Product logins

Find logins to all Clarivate products below.


Last Updated 23 December 2015
The psoriasis market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor-alpha (TNF-α) inhibitors is being challenged by the interleukin-12 and 23 (IL-12/23) inhibitor, ustekinumab (Janssen Biotech’s Stelara), and more recently, by the introduction of Novartis’s IL-17 inhibitor, secukinumab (Cosentyx), and Celgene’s oral phosphodiesterase-4 (PDE4) inhibitor, apremilast (Otezla). Novel oral therapies are generating interest following the remarkable uptake of Otezla in the first year of its launch. Thus, opportunities exist for developing safer and more-efficacious treatments in different drug classes for psoriasis; however, emerging therapies will have to deal with growing cost constraints and an increasingly competitive market. Additionally, the landscape will change further once biosimilars of frequently prescribed TNF-alpha inhibitors for psoriasis arrive in the major markets.

Related Market Assessment Reports

Report
Psoriasis – Landscape & Forecast – Disease Landscape & Forecast (G7)
The psoriasis therapy market has become increasingly lucrative due to the growing use of targeted agents. The newer IL-17 and IL-23 inhibitors (e.g., Eli Lilly’s Taltz, Johnson & Johnson…
Report
Psoriasis – Current Treatment – Current Treatment: Physician Insights – Psoriasis (EU5)
The psoriasis treatment landscape has significantly evolved in the past few years. A plethora of psoriasis treatments are available in the EU5, ranging from topical agents to conventional systemic…
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
With a drug-treated population of more than 3.3 million in the United States, France, Germany, and the United Kingdom, the moderate to severe psoriasis therapy market has been a lucrative space…
Report
Psoriasis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric Psoriasis (US)
Psoriasis affects pediatric, adolescent, and adult patients similarly; however, the effective management of pediatric psoriasis is more challenging owing to the limited number of treatments…
Report
Psoriasis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Psoriasis (US)
The treatment of adult psoriasis represents an increasingly lucrative market for nonconventional systemic therapies in the moderate to severe space, for which conventional systemic and topical…